“The success of the vaccine is important…you must also show your ability to win new orders”
While SK Bioscience entered the stock market on the 18th, analysts of pharmaceutical and bio companies analyzed that the company’s stock price could continue to rise further.
Securities experts first positively evaluated that SK Bioscience has signed a vaccine consignment production (CMO) and consignment development production (CDMO) contract with AstraZeneca and NovaVax, two vaccine developers for novel coronavirus infection (Corona 19). .
Kim Ji-ha, a researcher at Meritz Securities, said, “SK Bioscience has a content to make additional contracts if there is demand in addition to these two items.” There is also a possibility to win a contract.
Considering the average vaccine price and profit structure, Researcher Kim predicted SK Bioscience’s CDO and CDMO business performance at KRW 4969 billion this year and KRW 739.5 billion next year.
Reflecting this, the overall operating profit of SK Bioscience this year is expected to rise to 244.7 billion won, which is four times the annual forecast of last year (56.6 billion won).
An analysis suggests that vaccine candidates under development by SK Bioscience may also be a factor for the share price to rise further.
SK Bioscience’s self-developed candidate NBP2001 is undergoing phase 1 clinical trials, and GBP510, developed with the support of the Bill Gates Foundation and the Infectious Disease Innovation Association (CEPI), is undergoing phase 1/2 clinical trials, and is expected to proceed with phase 3 after the third quarter of this year.
Han Byeong-hwa, a researcher at Eugene Investment & Securities, said, “The current market cap of Curevec, Novavex, and BioEntech, which have grown rapidly due to Corona 19, is 16 trillion to 25 trillion won.” It predicted that the stock price will be formed at the level of the company’s market cap.”
However, as expectations for vaccines are high, conversely, it has been diagnosed that the success of the vaccine release will determine the long-term trend of the stock price.
One researcher pointed out, “As Corona 19 becomes endemic from a pandemic, it is estimated that there will be a global market of more than 10 trillion won per year.”
Some point out that SK Bioscience should demonstrate its ability to win orders even after the special situation of Corona 19.
“SK Bioscience has plans to promote CMO business in other areas such as gene therapy after IPO,” said Seo Mi-hwa, a researcher at Yuanta Securities. “It is important to confirm that it can receive CMO orders from new customers.” Diagnosed.
/yunhap news
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution